These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 26626183)
1. Adjuvant therapy of uterine clear cell carcinoma: a review. Xu Y; Hanna RK; Elshaikh MA Arch Gynecol Obstet; 2016 Mar; 293(3):485-92. PubMed ID: 26626183 [TBL] [Abstract][Full Text] [Related]
2. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. Thomas M; Mariani A; Wright JD; Madarek EO; Powell MA; Mutch DG; Podratz KC; Dowdy SC Gynecol Oncol; 2008 Feb; 108(2):293-7. PubMed ID: 18096208 [TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience. Armbruster SD; Previs R; Soliman PT; Westin SN; Fellman B; Jhingran A; Fleming ND Gynecol Oncol; 2019 Aug; 154(2):328-332. PubMed ID: 31221496 [TBL] [Abstract][Full Text] [Related]
4. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Murphy KT; Rotmensch J; Yamada SD; Mundt AJ Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1272-6. PubMed ID: 12654437 [TBL] [Abstract][Full Text] [Related]
5. Patterns of Care, Predictors, and Outcomes of Adjuvant Therapy for Early- and Advanced-Stage Uterine Clear Cell Carcinoma: A Population-Based Analysis. Gockley AA; Rauh-Hain JA; Anders AM; Meyer LA; Clemmer J; Lu KH; Clark RM; Schorge JO; del Carmen MG Int J Gynecol Cancer; 2016 May; 26(4):697-704. PubMed ID: 26825834 [TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and treatment outcomes for patients with surgically staged uterine clear cell carcinoma focusing on the early stage: A Taiwanese Gynecologic Oncology Group study. Hsu KF; Chou HH; Huang CY; Fu HC; Chiang AJ; Tsai HW; Chen JR; Cheng WF; Ke YM; Chang CC; Chen TH; Lin SH; Ho CM Gynecol Oncol; 2014 Sep; 134(3):516-22. PubMed ID: 25019570 [TBL] [Abstract][Full Text] [Related]
7. Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation. Olawaiye AB; Leath CA Gynecol Oncol; 2019 Nov; 155(2):365-373. PubMed ID: 31500893 [TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and treatment outcomes in surgically-staged non-invasive uterine clear cell carcinoma: a Turkish Gynecologic Oncology Group study. Sarı ME; Meydanlı MM; Türkmen O; Cömert GK; Turan AT; Karalök A; Şahin H; Haberal A; Kocaman E; Akbayır Ö; Erdem B; Numanoğlu C; Güngördük K; Sancı M; Gökçü M; Özgül N; Salman MC; Boyraz G; Yüce K; Güngör T; Taşkın S; Altın D; Ortaç UF; Ayık HA; Şimşek T; Arvas M; Ayhan A J Gynecol Oncol; 2017 Jul; 28(4):e49. PubMed ID: 28541637 [TBL] [Abstract][Full Text] [Related]
9. Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma. Zhang M; Yang TJ; Desai NB; DeLair D; Kollmeier MA; Makker V; Leitao MM; Abu-Rustum NR; Alektiar KM Brachytherapy; 2019; 18(1):38-43. PubMed ID: 30316723 [TBL] [Abstract][Full Text] [Related]
10. Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy? Boren TP; Miller DS Womens Health (Lond); 2010 Nov; 6(6):789-95. PubMed ID: 21118038 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study. Kuku S; Williams M; McCormack M Int J Gynecol Cancer; 2013 Jul; 23(6):1056-64. PubMed ID: 23765205 [TBL] [Abstract][Full Text] [Related]
12. Role of Adjuvant Therapy for Stage IA Serous and Clear Cell Uterine Cancer: Is Observation a Valid Strategy? Velker V; D'Souza D; Prefontaine M; McGee J; Leung E Int J Gynecol Cancer; 2016 Mar; 26(3):491-6. PubMed ID: 26825823 [TBL] [Abstract][Full Text] [Related]
13. National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma. Xiang M; English DP; Kidd EA Gynecol Oncol; 2019 Mar; 152(3):599-604. PubMed ID: 30551884 [TBL] [Abstract][Full Text] [Related]
14. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994. Craighead PS; Sait K; Stuart GC; Arthur K; Nation J; Duggan M; Guo D Gynecol Oncol; 2000 May; 77(2):248-53. PubMed ID: 10785473 [TBL] [Abstract][Full Text] [Related]
15. Prognostic determinants in patients with uterine and ovarian clear carcinoma. Rauh-Hain JA; Winograd D; Growdon WB; Schorge JO; Goodman AK; Boruta DM; Berkowitz RS; Horowitz NS; Del Carmen MG Gynecol Oncol; 2012 May; 125(2):376-80. PubMed ID: 22366593 [TBL] [Abstract][Full Text] [Related]
16. An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma. Liang LW; Perez AR; Cangemi NA; Zhou Q; Iasonos A; Abu-Rustum N; Alektiar KM; Makker V Int J Gynecol Cancer; 2016 Mar; 26(3):497-504. PubMed ID: 26825840 [TBL] [Abstract][Full Text] [Related]
17. A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy. Rauh-Hain JA; Costaaggini I; Olawaiye AB; Growdon WB; Horowitz NS; del Carmen MG Eur J Gynaecol Oncol; 2010; 31(3):284-7. PubMed ID: 21077469 [TBL] [Abstract][Full Text] [Related]
20. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers. Vogel TJ; Knickerbocker A; Shah CA; Schiff MA; Isacson C; Garcia RL; Goff BA J Gynecol Oncol; 2015 Jan; 26(1):25-31. PubMed ID: 25376917 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]